证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20170111 | --- | --- | --- | |--------------|-------------------------|------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 国泰君安 马丁 | | | 员姓名 | | | | 时间 | 2017 年 1 月 11 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | 上市公司接待 | | | | 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 | 、近期公司重大资产重组项目重新恢复审查，请介绍一 | | 动主要内容介 | | | | 绍 | | 下此次收购标的博日鸿的相关行业领域的情况和未来发展前 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20171208 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 东兴证券 龙海敏 | | | 员姓名 | | | | 时间 | 2017 年 12 月 8 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | 上市公司接待 人员姓名 | | 董事会秘书刘棣、投资部王瑜、证券部张金婷 | | 投资者关系活 | 1 | 、龙之杰的设备销售模式是怎样的？ | | 动主要内容介 | | | | 绍 | 答： | 龙之杰原有的销售 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20180511 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 民生证券 樊可 | | | 员姓名 | | | | 时间 | 2018 年 5 月 11 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | 上市公司接待 人员姓名 | | 董事会秘书刘棣、投资部刘书成、证券部张金婷 | | 投资者关系活 | 1 | 、公司原有主营业务生物医药自动化控制系统业务未来 | | 动主要内容介 | | | | 绍 | 发展情况如何？ | | | ...

Group 1: Company Overview and Business Direction - The company focuses on expanding its business in the pharmaceutical industry through horizontal and vertical integration, aiming to broaden its service coverage [2] - The intelligent manufacturing segment primarily serves pharmaceutical and bioproduct manufacturing enterprises, with a strong emphasis on automation and control systems [2] - The company has developed a comprehensive range of services covering traditional and new business areas, including traditional Chinese medicine and chemical synthesis [3] Group 2: Intelligent Manufacturing and Software Solutions - The company has four major categories of software products, including Manufacturing Execution Systems (MES), Manufacturing Tracking Systems (MTS), Supervisory Control and Data Acquisition (SCADA), and Warehouse Management Systems (WMS) [3] - These software solutions are crucial for implementing Industry 4.0 and enhancing the company's overall solution capabilities [3] Group 3: Focus on Traditional Chinese Medicine - The company views the development of traditional Chinese medicine as a key growth area, actively promoting its business in this sector [3] - In 2018, the company acquired Jin'an Pharmaceutical Machinery to integrate its automation control advantages with Jin'an's products, creating a complete intelligent manufacturing solution for traditional Chinese medicine [3] Group 4: Rehabilitation Medical Equipment Sector - The company aims to enhance its product line in the rehabilitation medical equipment sector to meet clinical rehabilitation needs [4] - The focus is on self-developed products that improve existing offerings and develop new products based on clinical requirements [4] - The company is expanding its sales network to cover urban and grassroots medical institutions, enhancing its market presence [4] Group 5: Future Development and Market Potential - The company plans to leverage its acquisition of Guangzhou Shiri to develop a comprehensive rehabilitation solution for maternal and child health [4] - The rehabilitation industry has significant market potential due to the aging population and the implementation of the three-child policy, prompting the company to continue its growth strategy [4]

Financial Performance - The company's operating revenue for Q3 2022 was ¥248,379,985.95, representing a year-on-year increase of 25.55%[4] - The net profit attributable to shareholders for the same period was ¥23,623,661.37, a significant increase of 103.18% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses reached ¥23,086,224.91, up by 93.26% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.0900, an increase of 125.00% compared to the same period last year[4] - Total operating revenue for Q3 2022 was 613,666,273.60 CNY, an increase from 549,418,732.10 CNY in Q3 2021, representing a growth of approximately 11.7%[18] - Net profit attributable to shareholders of the parent company reached 75,244,757.38 CNY, up from 60,497,601.62 CNY in the same period last year, reflecting a growth of about 24.4%[19] - The total profit for Q3 2022 was 87,460,490.85 CNY, compared to 64,335,075.23 CNY in Q3 2021, which is an increase of approximately 36%[18] - Basic and diluted earnings per share for Q3 2022 were both 0.28 CNY, up from 0.22 CNY in the same quarter last year, representing a growth of 27.3%[19] - The company reported a net profit margin improvement, although specific figures were not disclosed in the provided content[17] - The total comprehensive income for Q3 2022 was 77,914,778.97 CNY, an increase from 60,975,159.42 CNY in Q3 2021, reflecting a growth of approximately 28%[19] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,050,264,533.76, reflecting a growth of 5.98% from the end of the previous year[4] - As of September 30, 2022, total assets amounted to CNY 3,050,264,533.76, up from CNY 2,878,023,044.88 at the beginning of the year, reflecting a growth of 6%[16] - Current assets totaled CNY 1,569,654,337.63, compared to CNY 1,513,140,178.44 at the start of the year, indicating an increase of 3.7%[14] - Total liabilities reached CNY 1,107,395,914.84, compared to CNY 1,013,577,622.40 at the beginning of the year, an increase of 9.3%[16] - The company's total equity attributable to shareholders was ¥1,918,430,226.15, up by 4.14% from the previous year-end[4] - The company's equity attributable to shareholders was CNY 1,918,430,226.15, up from CNY 1,842,222,326.69, indicating a growth of 4.1%[16] Cash Flow and Investments - Cash flow from operating activities showed a negative net amount of ¥75,952,785.61, indicating a decline of 413.90% year-to-date[4] - The company reported a net cash flow from operating activities of -75,952,785.61 CNY, a decline from a positive cash flow of 24,196,550.35 CNY in Q3 2021[20] - The company's cash and cash equivalents decreased to CNY 141,844,424.53 from CNY 256,356,705.42, representing a decline of 44.5%[14] - Cash and cash equivalents at the end of the period were 117,495,909.16 CNY, down from 167,650,268.52 CNY at the end of Q3 2021, indicating a decrease of about 30%[21] - The company experienced a decrease in net cash flow from investing activities, reporting -73,095,416.98 CNY compared to -93,371,326.00 CNY in Q3 2021[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,539, with the top ten shareholders holding significant stakes[10] - The company's short-term borrowings increased by 38.27% compared to the beginning of the year, attributed to an increase in bank short-term loans[7] Research and Development - Research and development expenses increased to 45,131,474.61 CNY, compared to 35,457,404.13 CNY in Q3 2021, marking a rise of approximately 27.3%[18] Future Strategies - Future strategies include potential market expansion and new product development, although detailed plans were not specified in the content[17]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥446,711,611.07, representing a 6.79% increase compared to ¥418,300,409.10 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥51,621,096.01, up 5.63% from ¥48,870,461.16 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥48,062,950.29, reflecting a 9.67% increase from ¥43,825,731.14 in the same period last year[23]. - The net cash flow from operating activities was -¥35,997,732.88, a decline of 161.66% compared to -¥13,757,495.79 in the previous year[23]. - The total assets at the end of the reporting period were ¥2,916,409,405.41, an increase of 1.33% from ¥2,878,023,044.88 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were ¥1,892,841,941.89, up 2.75% from ¥1,842,222,326.69 at the end of the previous year[23]. - Basic earnings per share increased to ¥0.19, a rise of 5.56% from ¥0.18 in the same period last year[23]. - Diluted earnings per share also rose to ¥0.19, reflecting a 5.56% increase from ¥0.18 in the previous year[23]. - The weighted average return on net assets was 2.76%, slightly up from 2.73% in the previous year[23]. Business Strategy and Development - The company has established a "one body, two wings, dual-wheel drive" development strategy, focusing on becoming a service provider in the health sector, with operations in intelligent manufacturing and rehabilitation medical equipment[32]. - The intelligent manufacturing business primarily serves pharmaceutical and biological product manufacturers, providing comprehensive solutions that enhance automation, digitalization, and intelligence in production processes[33]. - The company aims to leverage favorable national policies to enhance its market position in intelligent manufacturing, particularly in the pharmaceutical sector, during the "14th Five-Year Plan" period[37]. - The company has integrated advanced technologies into its solutions, enabling clients to achieve higher production efficiency and quality control[41]. - The company has established a comprehensive rehabilitation solution service model, transitioning from single product sales to integrated solutions for medical institutions and rehabilitation centers[67]. Market and Industry Insights - The intelligent manufacturing sector is expected to experience significant growth, with government plans to have 70% of large-scale manufacturing enterprises achieve digitalization by 2025[38]. - The rehabilitation medical device business is part of a rapidly growing sector, with the demand for rehabilitation services in China reaching 460 million people in 2019[56]. - The number of rehabilitation hospitals in China was 739 as of 2020, accounting for 8% of the total number of specialized hospitals, indicating a supply-demand gap in rehabilitation resources[58]. - The government has introduced supportive policies for the rehabilitation industry, aiming to clarify future development goals and promote rapid growth in the sector[59]. Product and Service Offerings - The product line covers three major areas: rehabilitation assessment, rehabilitation training, and physical therapy, making it one of the companies with the most complete product lines in the domestic market[69]. - The company has developed specialized solutions for six major fields, including pain rehabilitation and neurological rehabilitation, enhancing its service offerings[71]. - The overall rehabilitation solution is characterized by deep service, providing comprehensive support from site planning to after-sales service, which shortens construction cycles compared to traditional models[72]. Research and Development - Research and development investment reached 12.7 million yuan, reflecting a commitment to technological innovation and new product development[90]. - Research and development expenses increased by 36.40% to 29.74 million yuan, driven by enhanced R&D efforts[99]. - The company completed certification for five new products, including the new air pressure circulation therapy device and upper and lower limb rehabilitation trainers, by the end of July 2022[91]. Financial Management and Investments - The company has not sold any significant assets or equity during the reporting period, maintaining its asset structure intact[126]. - The company has no overdue or unrecovered amounts from entrusted financial management, indicating a stable financial management approach[124]. - The company has achieved a cumulative investment of CNY 8,642.38 million for working capital, fully utilizing the allocated funds[120]. - The total amount of raised funds was 29,519.10 million, with 820.42 million invested during the reporting period[116]. Corporate Governance and Compliance - The company has maintained a fair and transparent information disclosure policy to protect investor interests[149]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[153]. - The company reported no significant litigation or arbitration matters during the reporting period[157]. - The half-year financial report was not audited, indicating a lack of external validation for the financial data presented[155]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,828[183]. - Beijing Liweit Investment Co., Ltd. held 18.76% of shares, totaling 51,209,771 shares, with 29,885,515 shares pledged[183]. - The second largest shareholder, Changsha Xinting Zhizhen Medical Investment Partnership, held 8.93% of shares, totaling 24,376,639 shares[183]. Environmental and Social Responsibility - The company emphasizes ecological civilization and has implemented measures to reduce carbon emissions through smart manufacturing solutions[148]. - The company has adopted a paperless office approach and energy-saving practices to promote environmental protection[148]. - The company has actively fulfilled its corporate social responsibility since its listing, ensuring compliance with laws and regulations related to environmental protection and employee rights[149].

Financial Performance - The company's revenue for Q1 2022 was ¥204,574,781.39, representing a 27.95% increase compared to ¥159,883,887.29 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was ¥17,728,313.32, up 32.18% from ¥13,412,026.83 in the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥17,464,571.14, reflecting a 42.81% increase from ¥12,228,961.09 year-on-year[3] - Total operating revenue for the current period reached ¥204,574,781.39, an increase of 28% compared to ¥159,883,887.29 in the previous period[20] - The net profit for the first quarter of 2022 was CNY 17,487,664.35, an increase of 31.5% compared to CNY 13,285,375.49 in the same period last year[21] - The total revenue from operating activities was CNY 218,424,156.89, up from CNY 184,753,234.67, reflecting a growth of approximately 18.2% year-over-year[25] - The total operating profit was CNY 19,130,126.10, an increase from CNY 12,724,472.13, representing a growth of 50.0%[21] - The company reported a total comprehensive income of CNY 18,046,499.43 for the quarter, compared to CNY 13,313,511.68 in the previous year, indicating a growth of 35.1%[22] Assets and Liabilities - The company's total assets at the end of Q1 2022 reached ¥2,901,953,745.81, a 15.45% increase from ¥2,513,682,150.62 at the end of the previous year[3] - Current assets totaled ¥1,473,642,736.72, a decrease of 2.6% from ¥1,513,140,178.44 at the beginning of the year[16] - Total liabilities stood at ¥1,017,472,970.77, a marginal increase from ¥1,013,577,622.40[18] - Total equity amounted to ¥1,884,480,775.04, down from ¥1,864,445,422.48, indicating a decrease of 1.1%[18] Cash Flow - Cash flow from operating activities showed an improvement, with a net outflow of ¥48,540,611.39, which is 31.22% less than the outflow of ¥70,571,036.50 in the same period last year[3] - The cash flow from operating activities showed a net outflow of CNY 48,540,611.39, an improvement from a net outflow of CNY 70,571,036.50 in the same quarter last year[25] - Cash and cash equivalents decreased to ¥138,819,626.36 from ¥256,356,705.42, representing a decline of 45.8%[16] - The cash and cash equivalents at the end of the period were CNY 114,951,016.71, an increase from CNY 90,084,031.13 year-over-year[26] Expenses - Research and development expenses increased by 48.97% compared to the previous year, indicating a stronger focus on innovation[9] - Sales expenses grew by 58.12% year-on-year, attributed to an expanded sales scope and increased personnel in smaller towns[9] - Operating costs included ¥122,013,838.73 in operating expenses, which rose from ¥99,887,927.58 year-over-year[20] - The company incurred financial expenses of CNY 2,889,822.86, a decrease from CNY 3,338,900.48, reflecting a reduction of approximately 13.4%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,061, indicating a stable shareholder base[11] Profitability Metrics - The weighted average return on equity improved to 0.96%, up from 0.76% in the previous year[3] - The company reported a net profit margin improvement, although specific figures were not disclosed in the provided data[19] - The basic and diluted earnings per share for the quarter were both CNY 0.06, compared to CNY 0.05 in the same period last year[22] Credit and Receivables - Accounts receivable increased to ¥447,153,127.03 from ¥431,686,874.09, reflecting a growth of 3.6%[16] - The company experienced a credit impairment loss of CNY 2,918,070.98, compared to a gain of CNY 1,761,000.58 in the previous year, indicating a significant change in credit conditions[21] - Inventory decreased slightly to ¥618,072,247.68 from ¥628,935,792.93, a reduction of 1.4%[16] Prepayments - The company reported a significant increase in prepayments, which rose by 68.68% compared to the beginning of the year, primarily due to procurement payments[8]

Financial Performance - The company's operating revenue for 2021 was ¥915,238,094.80, representing a 19.73% increase compared to ¥764,426,897.86 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥102,800,337.96, a significant increase of 70.24% from ¥60,386,907.20 in 2020[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥88,573,868.27, up 72.06% from ¥51,479,370.81 in 2020[18]. - The basic earnings per share for 2021 was ¥0.38, reflecting a 72.73% increase from ¥0.22 in 2020[18]. - The total assets at the end of 2021 amounted to ¥2,878,023,044.88, which is a 14.03% increase from ¥2,523,998,565.50 at the end of 2020[18]. - The net assets attributable to shareholders at the end of 2021 were ¥1,842,222,326.69, a 4.41% increase from ¥1,764,492,691.06 at the end of 2020[18]. - The net cash flow from operating activities for 2021 was ¥81,140,602.60, showing a decrease of 35.26% compared to ¥125,332,640.48 in 2020[18]. - The weighted average return on net assets for 2021 was 4.89%, an increase from 2.97% in 2020[18]. Quarterly Performance - Total revenue for Q1 was ¥159.88 million, Q2 was ¥258.42 million, Q3 was ¥197.83 million, and Q4 was ¥299.11 million, showing a strong performance in Q2 and Q4[21]. - Net profit attributable to shareholders for Q1 was ¥13.41 million, Q2 was ¥35.46 million, Q3 was ¥11.63 million, and Q4 was ¥42.30 million, indicating significant growth in Q2 and Q4[21]. - The net profit excluding non-recurring gains and losses for Q1 was ¥12.23 million, Q2 was ¥31.60 million, Q3 was ¥13.14 million, and Q4 was ¥31.61 million, reflecting a stable performance across the quarters[21]. - The net cash flow from operating activities was negative in Q1 at -¥70.57 million, but positive in Q2 at ¥56.81 million, Q3 at ¥37.95 million, and Q4 at ¥56.94 million, indicating improved cash flow management[21]. Business Strategy and Development - The company has established a dual-driven development strategy focusing on smart manufacturing and rehabilitation medical equipment, enhancing its market position in the health sector[30]. - The smart manufacturing sector is expected to benefit from favorable government policies, with a target for 70% of large manufacturing enterprises to achieve digitalization by 2025[34]. - The company aims to leverage its advanced technology and deep understanding of pharmaceutical processes to maintain its leading position in the smart manufacturing sector[37]. - The company has successfully expanded its business through strategic acquisitions, such as the acquisition of Longzhijie, which has strengthened its capabilities in the rehabilitation medical equipment field[30]. - The company is committed to a dual-driven development strategy, focusing on core businesses while exploring new markets and applications[82]. Market and Industry Insights - The rehabilitation medical device industry in China is a rapidly emerging sector, with growth rates exceeding the overall medical device industry[39]. - By the end of 2021, the population aged 65 and above in China was 201 million, accounting for 14.2% of the total population[40]. - The national policy support for the rehabilitation industry has intensified since June 2021, with multiple favorable policies being introduced[43]. - The "14th Five-Year" national plan emphasizes the expansion of elderly care services and the improvement of the health support system for the elderly[46]. - The Ministry of Industry and Information Technology's plan highlights "rehabilitation equipment" as one of the seven key areas for development in the medical equipment industry[47]. Research and Development - Research and development expenses exceeded ¥22 million, marking a 52% increase year-on-year, with the R&D team expanding to nearly 100 members, a 29% growth from the previous year[94]. - The company launched 5 new products and optimized 17 existing products during the reporting period[94]. - The company is committed to increasing R&D investment to enhance its product offerings and maintain a competitive edge in the rehabilitation medical equipment market[66]. - The company is focusing on technology innovation and has established a multi-dimensional R&D system to enhance its competitive edge in the industry[93]. - The company increased its R&D personnel to 306 in 2021, a 5.52% increase from 290 in 2020[128]. Product Development and Innovation - The company is focusing on expanding its product applications in rehabilitation and pain management sectors[126]. - The multifunctional electro-ultrasound combination therapy device (LGT-2900) is designed for various soft tissue injuries and has received domestic medical device registration and CE certification, with the first prototype developed[122]. - The company is advancing its research and development efforts in the field of medical devices, particularly in the areas of edema treatment and swallowing disorder diagnosis[120]. - The company aims to obtain FDA market access for its lymphatic therapy device, which is expected to enhance its position in the medical device market[120]. - The company is enhancing its "Smart Rehabilitation System" through IoT and AI technologies, improving the intelligence level of rehabilitation medical equipment[67]. Marketing and Sales Strategy - The company will enhance its marketing management by adopting innovative strategies and actively engaging with market information to establish long-term partnerships with key clients and increase sales from new customers[160]. - The company plans to increase its marketing budget by 15% to support brand awareness initiatives[194]. - The company has established stable distribution channels primarily targeting tertiary hospitals, with plans to expand into county and grassroots medical institutions[68]. - The company is actively promoting its brand through academic activities, enhancing its reputation and recognition among rehabilitation experts[69]. Governance and Investor Relations - The company emphasizes the importance of investor relations management and has established multiple communication channels for investor inquiries[177]. - The actual governance situation of the company does not significantly differ from the regulations set by the China Securities Regulatory Commission[178]. - The company has maintained a consistent governance structure in compliance with relevant laws and regulations[178]. - The participation rate of investors in the 2020 annual general meeting was 36.33%[180]. - The company has not experienced any changes in the board of directors, supervisors, or senior management during the reporting period[182].

北京诚益通控制工程科技股份有限公司 2021 年第三季度报告 证券代码：300430 证券简称：诚益通 公告编号：2021-065 北京诚益通控制工程科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 197,826,820.14 | -13.19% | 616,127,229.24 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥418,300,409.10, representing an increase of 80.96% compared to ¥231,152,218.59 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥48,870,461.16, a significant increase of 882.17% from a loss of ¥6,248,028.03 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥43,825,731.14, up 510.50% from a loss of ¥10,676,077.08 in the same period last year[19]. - The basic earnings per share increased to ¥0.180, compared to a loss of ¥0.020 per share in the previous year, marking a 1,000.00% increase[19]. - The total assets at the end of the reporting period were ¥2,662,801,619.66, reflecting a growth of 5.50% from ¥2,523,998,565.50 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased to ¥1,802,984,240.63, a rise of 2.18% from ¥1,764,492,691.06 at the end of the previous year[19]. - The net cash flow from operating activities improved to -¥13,757,495.79, a 61.79% reduction in loss compared to -¥36,008,088.67 in the previous year[19]. - The weighted average return on net assets was 2.73%, compared to -0.37% in the same period last year, indicating a positive turnaround[19]. Business Strategy and Development - The company has established a "dual-wheel drive" development strategy, focusing on smart manufacturing and rehabilitation medical equipment[26]. - The smart manufacturing business primarily serves pharmaceutical and biological product manufacturers, providing comprehensive smart manufacturing solutions[27]. - The company plans to expand its smart manufacturing business by focusing on "expanding fields" and "intelligentization" as development directions[39]. - The company has expanded its business scope into chemical synthesis and traditional Chinese medicine extraction, establishing a chemical synthesis division and acquiring Jin'an Pharmaceutical Machinery to enhance its automation control capabilities[40]. - The company has developed a comprehensive solution for industrial hemp purification and processing, and has established a subsidiary in the United States for business expansion in this area[40]. - The company has formed a system solution centered around intelligent logistics, batching, mixing, isolation, and packaging systems, extending its service offerings into formulation production[41]. - The company is focusing on multi-dimensional layout opportunities in the health sector, leveraging technologies like AI and robotics[84]. Market and Industry Insights - The pharmaceutical manufacturing industry has seen an increase in smart manufacturing maturity, with approximately 28.25% of companies reaching level two or above[29]. - The government has outlined plans to enhance manufacturing capabilities, aiming for over 50% of large-scale manufacturing enterprises to reach level two maturity by 2025[30]. - The rehabilitation medical device business is positioned in a rapidly growing sector, with China's rehabilitation demand reaching 460 million people in 2019, driven by an aging population and increasing surgical procedures[46]. - The number of rehabilitation projects covered by medical insurance in China has increased from 9 to 29 since 2010, expanding the consumer base and driving demand for rehabilitation services[49]. Product and Service Offerings - The company’s intelligent equipment solutions address multiple stages of drug formulation and packaging, ensuring efficient production flow[38]. - The company’s rehabilitation product line includes a wide range of devices for various therapeutic methods, making it one of the most comprehensive product lines in the domestic market[53]. - The company has launched comprehensive rehabilitation solutions to assist clients in establishing rehabilitation centers that meet national standards, enhancing service efficiency[56]. - The company is focusing on expanding its product line and enhancing the intelligence level of its rehabilitation equipment through IoT and AI technologies[60]. Financial Management and Investments - R&D expenses amounted to 9.96 million yuan, representing 10.26% of total revenue, an increase of approximately 44% compared to the same period last year[78]. - The total amount of raised funds was ¥295,190,990.86 after deducting issuance costs, with ¥751.22 million invested during the reporting period[102]. - The company has committed investments totaling CNY 30,876.72 million, with a cumulative investment of CNY 29,519.1 million, achieving a progress rate of 95.6%[105]. - The company has invested CNY 10,000 million in supplementary working capital, fully utilizing the funds as of the reporting period[105]. Governance and Compliance - The company maintains a robust governance structure to protect shareholder rights and ensure fair information disclosure[134]. - The company emphasizes quality management and customer satisfaction, establishing a strict quality control system[135]. - The company has strengthened employee training and revised operational protocols to enhance environmental compliance following the penalty[131]. - The company strictly adheres to national labor laws and regulations, ensuring fair employment practices and timely social insurance for employees[137]. Social Responsibility - The company has actively engaged in social responsibility initiatives, including organizing campus recruitment events to provide job opportunities for students[139]. - During the COVID-19 pandemic, the company donated multiple disinfection devices to various hospitals to support pandemic control efforts[140]. - The company reported an increase in tax contributions to the national and local governments, reflecting its commitment to social responsibility[139]. Risks and Challenges - The company faces intensified market competition as downstream industry clients demand higher product quality and comprehensive solutions[116]. - The company operates in technology-intensive industries, facing risks in product development such as long R&D cycles, high technical difficulty, and significant capital investment[117]. - Attracting and retaining high-quality technical and management talent is crucial for the company's future development, especially as organizational complexity increases[118]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 12,585[176]. - The largest shareholder, Beijing Liweit Investment Co., Ltd., holds 18.83% of the shares, totaling 51,209,771 shares[176]. - The total number of locked-up shares at the end of the period is 14,815,587 shares, with 2,108,525 shares released during the period[174].